VEEVA SYSTEMS Q1 FY27 earnings call VEEV

Veeva is embarking on the "next chapter" of its industry cloud, shifting from applications, data, and consulting to software, AI, data, and consulting. Falcon represents a disruptive move into "agentic labor," aiming to fully replace specific, high-volume, repetitive jobs previously done by humans. This initiative is distinct from Vault AI, which assists users within existing applications, and leverages Veeva's deep industry knowledge and application ecosystem to automate tasks like clinical trial document processing and safety case triage.

The company is promoting a new technical architecture called MAAP (Models, Agents, and Applications) to its biopharma customers. The goal is to enable an "agentic biopharma" where AI agents handle standardized, labor-intensive tasks, allowing human employees to focus on higher-value work. Examples include processing an estimated 100 million clinical trial documents annually for quality checks and categorization, and triaging adverse event reports to determine severity and related drugs. Veeva believes its structural advantage in life sciences, consulting, and application ownership positions it to lead in this area.

Crossix delivered a strong quarter, benefiting from a healthy and growing digital end market where pharma companies are increasing their investments. The business is driving market share gains through continuous product innovation, including new measurement capabilities for channels like OpenEvidence and Meta. Management expects Crossix to be a durable growth business long-term, with its diversified offerings in measurements and audiences reducing concentration risk.

Veeva continues to demonstrate strong execution in the Vault CRM space, securing significant global wins with major biopharma companies like Teva and Merck KGaA. Among the original "Top 20" biopharma list, Veeva has now won 10 decisions compared to Salesforce's 6, with 4 decisions remaining. The company maintains an overall win rate exceeding 80% for Vault CRM, with over 150 customers live and more than 40 migrations completed, indicating strong adoption and successful transitions.

The R&D business experienced healthy growth in Q1, particularly within DevCloud and Quality Cloud. This growth is attributed to the scaling of early-lifecycle products such as eCOA, RTSM, EDC, Safety, and LIMS. The company notes that deals in this area are becoming increasingly strategic due to the broader integration of offerings, including Falcon and Vault AI, which is generating significant momentum and excitement among customers, as evidenced by record attendance at recent R&D summits.

The acquisition of Ostro is a strategic move to enhance commercial engagement by providing a brand engagement platform for biopharma companies. Ostro enables compliant, instantaneous Q&A for healthcare professionals (HCPs) and patients, with biopharma driving the engagement. This platform integrates with digital channels like OpenEvidence and is crucial for unlocking "Commercial Evidence," offering unfiltered insights into HCP and patient needs to identify barriers to medicine access. Ostro is expected to play a growing role in the Commercial Cloud.

Veeva is actively leveraging AI internally across the company, utilizing both general-purpose and specialized tools. A significant area of application is product engineering, where tools like Claude Code are used to enhance efficiency and accelerate development. This internal AI adoption is expected to improve productivity, allowing the company to achieve more with potentially less hiring, with the benefits of increased output outweighing the associated token costs.

The development of the Falcon platform involves building the platform layer, assembling a dedicated team, and securing early adopter agreements to utilize customer data and documents for quality control and agent training. Veeva anticipates that smaller, nimble "Veeva Basics" customers will be among the first users of Falcon. This is due to their standardized configurations and processes, which make it easier for agents to operate effectively compared to larger enterprises with more customized Vault implementations.